Entries by Sean Kelly

Digital drug prediction informed by genetic analysis of stem cell-derived mini-brains from A-T patients

23rd November 2022 in , , /by

Research Project information Principal researcher: Dr Sam Nayler Institute:  QIMR Berghofer Medical Research Institute, Queensland, Australia Cost: £151,690.39 over 36 months in partnership with the A-T Society (UK), AEFAT (Spain) and BrAshA-T (Australia) Start Date: 1st of December 2022 What are the researchers proposing to do? In a previous study, Dr Sam Nayler and his team performed genetic […]

Trial REadiness in Ataxia Telangiectasia (TREAT-AT)

21st November 2022 in , , /by

Research Project information Principal researchers: Dr Rita Horvath and Dr Anke Hensiek Institute:  University of Cambridge, UK Cost: £250,000 over 36 months in partnership with the A-T Society (UK), AEFAT (Spain) and BrAshA-T (Australia) Start Date: 1st of January 2023 What are the researchers proposing to do? Ataxia Telangiectasia (A-T) is a devastating and untreatable inherited disease with neurological […]

Project Grants

14th November 2022 in /by

Our next project round is likely to open in late 2023, please contact tania.wheeler@actionforAT.org to be added to our mailing list so that we can keep you informed about all of our future funding opportunities. Triage When applying for funding, applicants should initially send a summary of their research proposal via email to tania.wheeler@actionforAT.org The […]

Study of natural killer cells in A-T pathogenesis and their therapeutic implications

13th October 2022 in , , /by

Research Project information Principal researchers: Dr Margherita Doria (right) and Dr. Maria Giovanna Desimio Institute:  Bambino Gesù Children’s Hospital, Italy Cost: £91,000 over 24 months in partnership with the A-T Society (UK), AEFAT (Spain) and BrAshA-T (Australia) Start Date: 1st of November 2022 What are the researchers proposing to do? The aim of this project is to identify […]

Brain-penetrating ATM gene therapy

26th August 2022 in , /by

Research Project information Principal researcher: Dr James Dixon Institute: University of Nottingham, UK Cost: £147,304.37 over 24 months in partnership with the AEFAT, A-T Society and BrAshA-T Start Date: 5th of September 2022 What are the researchers proposing to do? Dr James Dixon and team propose to combine gene therapy and editing to engineer an effective therapy to treat […]

Non-viral gene therapy for Ataxia Telangiectasia

8th June 2022 in , /by

Research Project information Principal researcher: Dr James Dixon Institute: University of Nottingham Cost: ~£105,000 over 24 months in partnership with A-TCP Project Completion Date: June 2022 Project Overview Gene therapy is a method to replace faulty genes with new copies. This is not readily applicable to the treatment of A-T due to the disease gene (ATM) being too […]